PBSV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBSV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pharma-Bio Serv's total inventories for the quarter that ended in Jan. 2025 was $0.00 Mil. Pharma-Bio Serv's average total inventories from the quarter that ended in Oct. 2024 to the quarter that ended in Jan. 2025 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Pharma-Bio Serv's Net-Net Working Capital per share for the quarter that ended in Jan. 2025 was $0.45.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Pharma-Bio Serv's Days Inventory for the three months ended in Jan. 2025 was 0.00.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Pharma-Bio Serv's Inventory-to-Revenue for the quarter that ended in Jan. 2025 was 0.00.
The historical data trend for Pharma-Bio Serv's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv Annual Data | |||||||||||||||||||||
Trend | Oct15 | Oct16 | Oct17 | Oct18 | Oct19 | Oct20 | Oct21 | Oct22 | Oct23 | Oct24 | |||||||||||
Total Inventories | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Pharma-Bio Serv Quarterly Data | ||||||||||||||||||||
Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | Apr24 | Jul24 | Oct24 | Jan25 | |
Total Inventories | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Pharma-Bio Serv (OTCPK:PBSV) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Pharma-Bio Serv's Net-Net Working Capital Per Share for the quarter that ended in Jan. 2025 is
Net-Net Working Capital Per Share (Q: Jan. 2025 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (12.435 | + | 0.75 * 2.682 | + | 0.5 * 0 | - | 4.081 |
- | 0 | - | 0) | / | 22.958 | ||
= | 0.45 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Pharma-Bio Serv's Days Inventory for the three months ended in Jan. 2025 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Jan. 2025 ) | / | Cost of Goods Sold (Q: Jan. 2025 ) | * | Days in Period |
= | 0 | / | 1.703 | * | 365 / 4 | |
= | 0.00 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharma-Bio Serv's Inventory Turnover for the quarter that ended in Jan. 2025 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Jan. 2025 ) | / | Average Total Inventories (Q: Jan. 2025 ) |
= | 1.703 | / | 0 | |
= | N/A |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharma-Bio Serv's Inventory to Revenue for the quarter that ended in Jan. 2025 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Jan. 2025 ) | / | Revenue (Q: Jan. 2025 ) |
= | 0 | / | 2.471 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Pharma-Bio Serv's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Elizabeth Plaza | 10 percent owner | 363 DORADO BEACH EAST, DORADO PR 00646 |
Altura Victor Sanchez | officer: President and CEO | C/O PHARMA-BIO SERV, INC., 6 ROAD 696, DORADO PR 00646 |
San Juan Holdings | 10 percent owner | 255 PONCE DE LEON, SUITE 305 MCS PLAZA, SAN JUAN PR 00917 |
Pedro J Lasanta | officer: Chief Financial Officer | 373 MENDEZ VIGO, STE 110, DORADO PR 00646 |
Dov Perlysky | director | 2 LAKESIDE DRIVE WEST, LAWRENCE NY 11559 |
L P Venturetek | 10 percent owner | C/O DAVID SELENGUT ELLENOFF GROSSMAN, 370 LEXINGTON AVENUE 19TH FLOOR, NEW YORK NY 10017 |
Barron Partners Lp | 10 percent owner | 730 FIFTH AVENUE, 25TH FLOOR, NEW YORK NY 10019 |
Manuel O Morera | officer: Chief Financial Officer | 373 MENDEZ VIGO, SUITE 110, DORADO PR 00646 |
Mark A Fazio | officer: Exec. Vice President and COO | P O BOX 1026 GREEN STREET, PERKASIE PA 18944 |
Kirk Wheeler Michel | director | 209 EAST TRYON STREET, HILLSBOROUGH NC 27278 |
Irving L Wiesen | director | 1273 NORTH AVENUE, APT 1E 7, NEW ROCHELLE NY 10804 |
Howard Spindel | director | 39 BROADWAY SUITE 3300, NEW YORK NY 10028 |
Nelida Plaza Rodriguez | officer: Vice President and Secretary | G11 CALLE MADRE PERLA URB, DORADO DEL MAR, DORADO PR 00646 |
Krovim Llc | director, 10 percent owner, officer: Manager | P.O. BOX 339, LAWRENCE NY 11559 |
From GuruFocus
By ACCESSWIRE • 12-21-2023
By ACCESSWIRE • 02-12-2024
By ACCESSWIRE ACCESSWIRE • 09-15-2020
By ACCESSWIRE • 03-19-2024
By ACCESSWIRE ACCESSWIRE • 01-06-2021
By [email protected] [email protected] • 03-17-2020
By ACCESSWIRE • 09-15-2023
By ACCESSWIRE ACCESSWIRE • 03-01-2023
By ACCESSWIRE ACCESSWIRE • 06-15-2021
By ACCESSWIRE • 09-17-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.